Candriam S.C.A. Mersana Therapeutics, Inc. Transaction History

Candriam S.C.A.

$16.9 Billion
Q4 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$3.08 - $9.55 $1.69 Million - $5.23 Million	-547,371 Reduced 18.47%	2,415,477 $7.95 Million
Q1 2023 May 12, 2023	BUY	$4.0 - $7.02 $1.08 Million - $1.9 Million	270,000 Added 10.03%	2,962,848 $12.2 Million
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $1.1 Million - $1.53 Million	195,000 Added 7.81%	2,692,848 $15.8 Million
Q3 2022 Nov 10, 2022	BUY	$4.63 - $8.0 $2.35 Million - $4.06 Million	507,289 Added 25.48%	2,497,848 $16.9 Million
Q2 2022 Aug 03, 2022	BUY	$2.84 - $5.0 $413,890 - $728,680	145,736 Added 7.9%	1,990,559 $9.2 Million
Q1 2022 May 13, 2022	SELL	$3.74 - $6.63 $665,989 - $1.18 Million	-178,072 Reduced 8.8%	1,844,823 $7.36 Million
Q3 2021 Nov 09, 2021	BUY	$8.56 - $14.47 $428,000 - $723,500	50,000 Added 2.53%	2,022,895 $19.1 Million
Q2 2021 Jul 20, 2021	BUY	$13.28 - $18.07 $11.3 Million - $15.4 Million	850,722 Added 75.81%	1,972,895 $26.8 Million
Q1 2021 Apr 29, 2021	BUY	$15.31 - $26.52 $428 - $742	28 Added 0.0%	1,122,173 $28.7 Million
Q4 2020 Jan 22, 2021	BUY	$16.84 - $27.59 $9 Million - $14.7 Million	534,437 Added 90.94%	1,122,145 $29.9 Million
Q3 2020 Oct 19, 2020	SELL	$16.2 - $25.7 $130,167 - $206,499	-8,035 Reduced 1.35%	587,708 $10.9 Million
Q2 2020 Jul 23, 2020	BUY	$5.24 - $23.4 $3.12 Million - $13.9 Million	595,743 New	595,743 $13.9 Million
Q2 2018 Aug 14, 2018	SELL	$14.2 - $22.68 $511,200 - $816,480	-36,000 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$13.56 - $18.48 $325,440 - $443,520	24,000 Added 200.0%	36,000 $568,000
Q4 2017 Feb 07, 2018	BUY	$14.95 - $19.9 $179,400 - $238,799	12,000	12,000 $197,000

Others Institutions Holding MRSN

# of Institutions

130

Shares Held

104M

Call Options Held

58.5K

Put Options Held

471K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $56.4M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account